AFL — Aflac Incorporated

Aflac Inc. Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Earnings per Diluted Share: $3.08
• Adjusted Earnings per Diluted Share: $2.49, a 15.3% increase year-over-year.
• Net Earned Premiums: Increased by 2.5% in the U.S. and decreased by 4% in Japan.
• Premium Persistency: 79% in the U.S. and 93.3% in Japan.
• Benefit Ratios: Japan at 39.3% (down nearly 10 percentage points year-over-year), U.S. at 45.6% (200 basis points lower than Q3 2024).
• Adjusted Return on Equity (ROE): 19.1%, 22.1% excluding foreign currency remeasurement.
• Capital Deployment: $1 billion in share repurchases and $309 million in dividends, totaling $1.3 billion returned to shareholders.

2. Strategic Updates and Business Highlights

• Aflac Japan:
  • Sales increased by 11.8% year-over-year, with a notable 42% rise in cancer insurance sales driven by the Miraito product.
  • Ongoing emphasis on third sector protection and the introduction of the repriced Tsumitasu product, which has shown positive sales growth.
• Aflac U.S.:
  • New sales of $390 million, a 2.8% year-over-year increase.
  • Focus on profitable growth through strong underwriting discipline and expense management.
  • Successful initiatives in group life, disability, and dental products, with dental operations stabilizing and showing a 40% increase year-to-date.

3. Forward Guidance and Outlook

• Japan Benefit Ratio: Expected to be in the 58% to 60% range for 2025, with pretax profit margins projected between 35% to 38%.
• U.S. Benefit Ratio: Anticipated to be at the lower end of the 48% to 52% range, with pretax profit margins expected in the upper end of the 17% to 20% range.
• Continued focus on capital management and strong returns on capital.

4. Bad News, Challenges, or Points of Concern

• Japan:
  • A decline in net earned premiums by 4%, although underlying earned premiums showed a smaller decline of 1.2%.
  • Potential headwinds from the impact of reinsurance and policies reaching paid-up status.
• U.S.:
  • Core voluntary product sales have decreased, with competition from brokers favoring group products over individual offerings.
  • Increased expense ratio in the U.S. to 38.9%, driven by a one-time termination fee and advertising spend.
• Claims Trends: Rising benefit ratios due to enhancements in policies and a catch-up effect from previously low claims during the pandemic, particularly in cancer claims.

5. Notable Q&A Insights

• Sales Dynamics: Brokers are increasingly leaning towards group products, impacting individual product sales. A focus on increasing the number of active agents is crucial for future growth.
• Cancer and Tsumitasu Products: Strong performance in cancer insurance sales and positive reception for the repriced Tsumitasu product, which is expected to attract a younger demographic.
• M&A Strategy: Aflac is cautious about pursuing M&A opportunities, preferring to focus on organic growth and enhancing existing capabilities before considering larger acquisitions.
• Private Credit Outlook: Aflac maintains a disciplined approach to private credit investments, with no immediate concerns regarding credit deterioration in their portfolio.

This summary encapsulates Aflac's performance and strategic direction for Q3 2025, highlighting both achievements and challenges faced by the company.